scholarly journals Vascular Complications and Long-Term Administration of Oral Hypoglycemic Agents in Patients with Diabetes Mellitus

1978 ◽  
Vol 124 (3) ◽  
pp. 205-222 ◽  
Author(s):  
AKIRA OHNEDA ◽  
YOSHISUKE MARUHAMA ◽  
HIROSHI ITABASHI ◽  
SHIN-ICHI OIKAWA ◽  
TAKASHI KOBAYASHI ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Vascular Complications ◽  
Hypoglycemic Agents ◽  
Oral Hypoglycemic Agents ◽  
Patients With Diabetes ◽  
Term Administration

scholarly journals Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors

2010 ◽  
Vol 13 (2) ◽  
pp. 69-75 ◽  
Author(s):  
Alexander Sergeevich Ametov ◽  
Ekaterina Vladimirovna Karpova
Keyword(s):  
Diabetes Mellitus ◽  
Glycemic Control ◽  
High Efficiency ◽  
Combined Therapy ◽  
Vascular Complications ◽  
Hypoglycemic Agents ◽  
International Studies ◽  
Oral Hypoglycemic Agents ◽  
Control Blood Glucose ◽  
Oncological Diseases

Diabetes mellitus (DM) is believed to be the third most frequent direct cause of death after cardiovascular and oncological diseases. Therefore, solutionof DM-related problems is a major challenge facing health authorities in many countries. No doubt, strict control of glycemia is an indispensablecondition for the reduction of the frequency of diabetic complications. Indeed, many strategies developed in the recent years allowed metabolic controlin DM patients to be significantly improved. Basic and clinical research of the last decade provided a basis for the development of highly promisingtrends in the treatment of CD2, such as the use of incretins. Inhibitors of dipeptylpeptidase-4 (DPP-4) including Galvus (vildagliptin) and GalvusMet (vildagliptin + metformin) have been available in this country for the last 2 years. International studies showed high efficiency and safety of bothagents. They help to achieve adequate glycemic control in the absence of side effects and complications. Galvus significantly reduces daily variabilityof glycemia that is known to be a risk factor of severe vascular complications of DM. Another advantage of these drugs is they can be used by agedpatients at risk of cardiovascular disorders suffering hypertension. An example of combined therapy using Galvus Met in a DM2 patient is presenteddemonstrating markedly improved glycemic control, blood glucose dynamics, and quality of life. Galvus and Galvus Met can be prescribed as aninitial treatment in combination with all traditional oral hypoglycemic agents and insulin.

scholarly journals Treatment of influenza and other acute respiratory viral infections in patients with diabetes mellitus

2019 ◽  
Vol 91 (10) ◽  
pp. 39-47 ◽  
Author(s):  
I G Sitnikov ◽  
V Kh Fazylov ◽  
E V Silina
Keyword(s):  
Diabetes Mellitus ◽  
Antiviral Therapy ◽  
Viral Infections ◽  
Clinical Performance ◽  
Drug Prescription ◽  
Antiviral Drug ◽  
Hypoglycemic Agents ◽  
Oral Hypoglycemic Agents ◽  
Patients With Diabetes ◽  
Respiratory Viral Infections

Purpose of the study. The study of the influenza and ARVI clinical performance, the development of patients with diabetes mellitus, evaluation of the effectiveness and safety application of antiviral therapy, carried out in the framework of routine clinical practice. Materials and methods. 126 patients aged from 22 to 83 years (27.8% of men) with ARVI or influenza that occurred with medical care during the first 5 days of the disease (60.3% in the first 48 hours) are included. All patients suffer from diabetes, for the treatment of which oral hypoglycemic agents or insulins were constantly taken. The patients were divided into two groups: the first group received standard symptomatic treatment of ARVI; antiviral drug Kagocel. Results and conclusion. Diabetes and other acute respiratory viral infections. There is an increase in the incidence of bacterial complications - 2.2 times, an increase in the frequency of systemic antibiotics - 2.3 times. The purpose of the drug prescription led to a more rapid regression of all the symptoms of influenza and ARVI, but the most striking positive dynamics was observed in the symptoms of general weakness and headache. The prescription of Kagocel was accompanied by a 58% reduction in the number of bacterial complications and a 53% reduction in the use of antibiotics, which led to a reduction in the number of cases of the disease and an improvement in initial diseases, with an frequency increase in 1.8 times. The most significant effect achieved with early treatment and early initiation of antiviral therapy (in the first 48 hours of the disease).

scholarly journals Microvascular complications among patients with diabetes: An emerging health problem in Saudi Arabia

2019 ◽  
Vol 16 (3) ◽  
pp. 227-235 ◽  
Author(s):  
Asirvatham Alwin Robert ◽  
Mohamed Abdulaziz Al Dawish
Keyword(s):  
Diabetes Mellitus ◽  
Saudi Arabia ◽  
Microvascular Complications ◽  
Adult Population ◽  
Vascular Complications ◽  
Kingdom Of Saudi Arabia ◽  
Patients With Diabetes ◽  
The Government ◽  
Prevalence Of Diabetes Mellitus

Diabetes mellitus, besides disrupting the carbohydrate metabolism process, also induces vascular disease and impacts nearly all the types and sizes of blood vessels. In fact, vascular complications cause majority of the morbidity, hospitalizations and mortality of patients with diabetes mellitus. Retinopathy, nephropathy and neuropathy (microvascular complications) impact hundreds of millions of diabetics and normally target those having long-term or uncontrolled forms of the disease; however, these disorders can also exist at the time of diagnosis or in those yet to be diagnosed. The Kingdom of Saudi Arabia is the biggest country in the Middle East that occupies around four-fifths of the Arabian Peninsula supporting a population of more than 33.3 million people. The prevalence of diabetes mellitus is increasing at an alarming rate in Saudi Arabia. Over 25% of the adult population is suffering and that figure is projected to more than double by 2030. In fact, diabetes mellitus has approximately registered a 10-fold upsurge in the past three decades in Saudi Arabia. However, the prevalence and risk factors of microvascular complications in diabetes mellitus patients have not yet been clearly documented in Saudi Arabia. Hence, in this review, we aim to provide an overview of the microvascular complications among patients with diabetes in Saudi Arabia, utilizing data from the currently available published literature. This is an attempt to facilitate the government and healthcare systems aware of the enormous worth of prevention, early detection and appropriate management of such microvascular complications.

A Critique of Methods in Reported Studies of Long-term Vascular Complications in Patients with Diabetes Mellitus

Diabetes ◽  
1973 ◽  
Vol 22 (3) ◽  
pp. 160-174 ◽  
Author(s):  
M. H. Kaplan ◽  
A. R. Feinstein
Keyword(s):  
Diabetes Mellitus ◽  
Vascular Complications ◽  
Patients With Diabetes

scholarly journals Glycemic control in patients with diabetes mellitus on hemodialysis

2019 ◽  
Vol 91 (10) ◽  
pp. 124-134 ◽  
Author(s):  
K G Lobanova ◽  
A S Severina ◽  
S A Martinov ◽  
M Sh Shamkhalova ◽  
M V Shestakova
Keyword(s):  
Diabetes Mellitus ◽  
Glycemic Control ◽  
Glycated Albumin ◽  
Glucose Monitoring ◽  
Hypoglycemic Agents ◽  
Routine Practice ◽  
Oral Hypoglycemic Agents ◽  
Patients With Diabetes ◽  
The Moment

Achievement of stabilization of carbohydrate metabolism in patients with diabetes mellitus, receiving renal replacement therapy with hemodialysis, is a significant problem in endocrinology. It has to do with multiple factors of this cohort of patients, which affect the level of glycemia, pharmacokinetic of drugs, the efficiency of glycemic control. At the moment, the most efficiency method of glycemic control in patients with type 2 diabetes mellitus on hemodialysis is insulin therapy in the basis - bolus regime by analogues of human insulin. The use of oral hypoglycemic agents is significantly limited. The hemoglobin A1c (HbA1c) remains the main parameter of glycemic control. The simultaneous use of continuous glucose monitoring allows to reveal the true level of glucose of the blood and to carry out the timely correction of therapy in order to achieve targets for glycemic control and to decrease the risk of hypoglycemic episodes. At the moment other glycemic control markers such as glycated albumin and fructosamine are described. However, in routine practice at the moment these indicators are not used due to the lack of sufficient evidentiary base of their use in this cohort of patients.

scholarly journals On diabetes mellitus register

1995 ◽  
Vol 41 (3) ◽  
pp. 4-7 ◽  
Author(s):  
I. I. Dedov ◽  
Yu. I. Suntsov ◽  
S. V. Kudryakova ◽  
S. G. Ryzhkov
Keyword(s):  
Diabetes Mellitus ◽  
Hypoglycemic Agents ◽  
Diabetes Incidence ◽  
Oral Hypoglycemic Agents ◽  
Systematic Account ◽  
Incidence And Mortality ◽  
Patients With Diabetes ◽  
Specialized Care ◽  
Automated Information System ◽  
The Moment

The modern system of medical and statistical observation, which has developed in Russia, does not allow a sufficiently complete assessment of the real epidemiological situation in relation to such a disease as diabetes mellitus (DM). Meanwhile, the damage associated with the incidence of diabetes mellitus, early disability and mortality from it, as well as the cost of treatment of patients are very significant. Planning specialized care for patients, providing them with a sufficient amount of medicines, as well as training the necessary number of specialists and specially trained average staff to work with patients with diabetes requires a clear knowledge of their needs. In this regard, there is a need for a more complete and systematic account of not only the fact of disease or death, but also the presence of complications of diabetes, the need for insulin, oral hypoglycemic agents, the causes of disability and death of patients with diabetes. In world practice, the above problems are solved by creating a register of SD. In its modern view, the diabetes register is an automated information system for recording the results of continuous medical-statistical monitoring of diabetes incidence and mortality in connection with it. The system provides for monitoring of the patient from the moment of his inclusion in the register until his death. The latter involves the registration of information about the patient with diabetes in various aspects: the presence of complications, their dynamics, treatment and availability of drugs, as well as the nature of the course of diabetes, the direct causes of death of the patient. The amount of information recorded depends on the objectives pursued by the organizers of the register.

Effectiveness and Safety of Oral Hypoglycemic Agents as Initial Treatment in Comparison to Insulin Injection in Newly Diagnosed Type 2 Diabetes Mellitus

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1240-P
Author(s):  
XI CHEN ◽  
YUFAN WANG ◽  
AIFANG ZHANG ◽  
NIAN WANG ◽  
NA LI
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Initial Treatment ◽  
Insulin Injection ◽  
Hypoglycemic Agents ◽  
Newly Diagnosed ◽  
Oral Hypoglycemic Agents
Sign in / Sign up

Export Citation Format

Share Document